Actively Recruiting
Phase 3 Study of Disitamab Vedotin Combined with BCG Versus BCG Alone in Adults with HER2-Positive, High-Risk Non-Muscle-Invasive Bladder Cancer
Led by Fudan University · Updated on 2026-07-21
182
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of Disitamab Vedotin combined with Bacillus Calmette-Gue9rin BCG in people with high-risk non-muscle-invasive bladder cancer that has not spread outside the bladder and has been surgically removed. This Phase III trial aims to compare this combination against BCG alone in patients who have not previously received BCG treatment and whose tumors express the HER2 marker. Participants are randomly assigned to one of two groups one receives Disitamab Vedotin plus BCG during both induction and maintenance phases, and the other receives BCG alone with the same schedule. Disitamab Vedotin is an antibody-drug conjugate targeting HER2, and BCG is an immunotherapy approved for this cancer type. The study is designed to see if adding Disitamab Vedotin can improve event-free survival compared to BCG by itself. During the study, participants will be monitored regularly for up to 55 months after the first participant is randomized to measure event-free survival. Additional outcomes assessed include overall survival, complete response rates at 6 and 12 months for certain patients, disease-specific survival, and health-related quality of life. Researchers will conduct various evaluations and follow-ups throughout the trial period, which lasts until December 2030.
CONDITIONS
Brief Title
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Research Team
Y
Yi jun Shen, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here